Canada Specialty Pharmacy Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2030 |
 Market Size (Base Year) |
|
 Market Size (Forecast Year) |
USD 14,192.50 |
 CAGR |
% |
| Major Markets Players |
>加拿大专科药房市场，按服务类型（临床服务、运营服务和其他服务）、类型（大型药房福利管理者和小型独立药房服务提供商）、疾病（贫血、癌症、艾滋病毒、不孕症、多发性硬化症、类风湿性关节炎、生长激素缺乏症、丙型肝炎病毒、血友病、牛皮癣、肺动脉高压、克罗恩病、囊性纤维化、免疫缺陷、骨关节炎、幼年特发性关节炎、溃疡性结肠炎等）划分 - 行业趋势和预测到 2030 年。
加拿大专业药房市场分析及规模
专业药房模式旨在为患有慢性疾病和复杂疾病的患者提供全面而协调的护理模式，实现卓越的临床和经济效果，并加快患者获得护理的途径。专业药房为重病患者提供针对其病情的处方药，提供这些药物所需的患者护理服务，并为面临这些改变生活、有时甚至挽救生命但通常价格昂贵的药物报销挑战的患者提供支持。
老年人口的增加预计将推动该领域的增长。然而，严格的监管框架预计将阻碍加拿大专业药房市场的增长。
Data Bridge Market Research 分析，加拿大专科药房市场预计到 2030 年将达到 141.925 亿美元的价值，预测期内的复合年增长率为 11.3%。临床服务是加拿大专科药房市场中最大的部分。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史年份 |
2021 (可定制至 2020-2015) |
|
定量单位 |
收入（百万美元） |
|
涵盖的领域 |
按服务类型（临床服务、运营服务和其他服务）、类型（大型药房福利管理者和小型独立药房服务提供商）、疾病（贫血、癌症、艾滋病毒、不孕症、多发性硬化症、类风湿性关节炎、生长激素缺乏症、丙型肝炎病毒、血友病、牛皮癣、肺动脉高压、克罗恩病、囊性纤维化、免疫缺陷、骨关节炎、幼年特发性关节炎、溃疡性结肠炎等） |
|
覆盖国家 |
加拿大 |
|
涵盖的市场参与者 |
McKesson Canada、Bayshore HealthCare、SRx Health、Sentrex Health Solutions、Sobeys Inc.、PHARMASAVE、Lovell Drugs、Create Compounding Ltd.、Dynasty Pharmacy、Resident Care Pharmacy、Pace Pharmacy、Northmount Pharmacy and Compounding Lab、Medicine Centre、riverviewguardian.ca、Brunskillpharmacy、Extend Pharmacy、Sherman Specialty Pharmacy、Quiick Medicine、Allcures Pharmacy、Alpine Drug Mart IDA、PharmaChoiceAnchor Compounding Pharmacy、Andreen's Pharmacy、Balanced Health Integrative Pharmacy、Bains Pharmacy、Shoppers Drug Mart Specialty Health Network Inc. 和 MEDS 等 |
市场定义
专业药房与传统药房的不同之处在于，它们协调患者护理和疾病管理的许多方面。它们旨在以标准化的方式提供具有特殊处理、储存和分发要求的药物，以实现规模经济。专业药房还旨在通过与临床医生的密切接触和管理，改善患有复杂、通常是慢性和罕见疾病的患者的临床和经济结果。专业药房雇用医疗保健专业人员来教育患者，帮助确保适当使用药物，促进依从性，并尽量避免不必要的费用。其他支持系统协调治疗患者的临床医生之间的信息共享，并帮助患者找到资源以支付自付费用。
加拿大专科药房市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。以下内容将详细讨论所有这些内容：
驱动因素/机遇
- 慢性病和罕见病发病率不断上升
随着经济增长，人们越来越关注长期健康和保健。患有慢性病的患者需要定期监测自己的健康状况。专科药房服务有助于管理慢性病和罕见病，因为有专门的药物可用于治疗糖尿病、心力衰竭或慢性阻塞性肺病 (COPD)、癌症等慢性病，以及自身免疫性疾病等罕见病，即嗜酸性肉芽肿性多血管炎 (EGPA)、格林-巴利综合征、川崎病等。其服务包括药物配发和提供其他医疗援助。
- 老年人口不断增加
由于老年人口更容易患慢性疾病和受伤，加拿大老年人口疾病和受伤的患病率导致对专业药房服务的需求，以监测和护理他们的健康。因此，老年人口及其不断上升的患病率在推动专业药房市场方面发挥着重要作用。这些服务使用数字工具和富有同情心的临床服务的独特组合来提供生育药物、护士管理的家庭输液，并为患有类风湿性关节炎、癌症、艾滋病毒甚至罕见疾病的人提供护理。
- 专业药店的新兴市场
专业药房市场增长的一个主要因素是人口老龄化。不健康的生活方式导致的糖尿病以及痴呆症、阿尔茨海默病和帕金森病在老年人口中很常见。从 2015 年到 2021 年，老年人的数量预计将首次超过 14 岁及以下儿童的数量。到 2036 年，老年人的数量可能达到 990 万至 1090 万人。根据中等增长情景，到 2036 年，80 岁及以上人口的数量预计将翻一番，达到 330 万人。100 岁及以上人口可能会增加两倍，达到 20,000 多人。除了老年人口之外，GDP、人口密度和专业药房市场准入的改善也创造了增长机会。
限制/挑战
- 严格的监管框架
加拿大的医药政策由联邦政府和省政府共同制定，联邦政府负责保护处方药生产商的知识产权（专利）、初始审批、标签和整体市场竞争，省政府负责并有权资助所有医疗服务，包括处方药。此外，专科药物属于高风险药物，包括用于治疗癌症等慢性疾病和自身免疫性疾病等罕见疾病的药物。因此，这些药物的分销和制造有不同的监管框架。
- 专业药房资金不足
加拿大地区慢性病死亡率很高，其中一个重要原因是专科药房资金不足，导致专科药房数量减少。
专科药房经营慢性病和罕见病的专科药物。专科药房是经国家许可的药房，专门或主要为患有严重疾病且需要复杂疗法的患者提供药物。这些药物和疗法的自付费用非常高，这反过来又使专科药房的起步成本非常高，需要大量的投资和资金。政府的疏忽援助和举措导致这些药房的衰落。
因此，专业药房资金不足可能会对加拿大专业药房市场的增长构成挑战。
新冠肺炎疫情对加拿大专科药房市场的影响
新冠病毒疫情影响了加拿大专业药房行业的四个主要领域：产品采购、产品发布和分销、收购和获取以及治疗和护理管理。专业药房通过与联邦和省政府机构密切合作，应对医疗保健系统在抗击 COVID-19 疫情方面遇到的挑战，从而脱颖而出。这些挑战包括探索新的工作方式、提高 COVID-19 的检测能力和结果跟踪能力，并最终致力于开发、生产和提供安全有效的疫苗和治疗方法。制造商正在做出各种战略决策，以在 COVID-19 疫情后实现复苏。参与者正在为专业药房市场实施多项战略和计划。
近期发展
- 2022 年 3 月，BioScript 解决方案和 NeonMind 宣布建立战略合作伙伴关系，以扩大介入性精神病治疗专科诊所网络。此次合作将利用 BioScript 解决方案在广泛的全国社区输液诊所网络中，扩大加拿大人获得 NeonMind 介入性精神病学和独特治疗计划的机会
加拿大专科药房市场范围
加拿大专业药房市场根据服务类型、类型和条件分为三个部分。这些部分之间的增长将帮助您分析行业中的主要增长部分，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，以确定核心市场应用。
- 服务类型
- 临床服务
- 运营服务
- 其他服务
根据服务类型，加拿大专业药房市场分为临床服务、运营服务和其他服务。
- 类型
- 大型药店福利管理者 (PBM)
- 小型独立药房服务提供商
根据类型，加拿大专业药房市场细分为大型药房福利管理者（PBM）和小型独立药房服务提供商。
- 健康）状况
- 贫血
- 癌症
- 艾滋病病毒
- 不孕不育
- 多发性硬化症
- 类风湿关节炎
- 生长激素缺乏
- 丙型肝炎病毒
- 血友病
- 银屑病
- 肺动脉高压
- 克罗恩病
- 囊性纤维化
- 免疫缺陷
- 骨关节炎
- 幼年特发性关节炎
- 溃疡性结肠炎
- 其他的
根据病情，加拿大专科药房市场细分为贫血、癌症、艾滋病毒、不孕症、多发性硬化症、类风湿性关节炎、生长激素缺乏症、丙型肝炎病毒、血友病、牛皮癣、肺动脉高压、克罗恩病、囊性纤维化、免疫缺陷、骨关节炎、幼年特发性关节炎、溃疡性结肠炎等。
加拿大专业药房市场区域分析/见解
对加拿大专业药房市场进行了分析，并按上述国家、服务类型、类型和条件提供了市场规模见解和趋势。
加拿大专科药房市场正在增长，因为对专科药物的需求不断增加，分销渠道的增加以及慢性病患病率的不断上升预计将推动市场的增长。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势和波特五力分析以及案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税的影响以及贸易路线。
竞争格局和加拿大专业药房市场份额分析
加拿大专业药房市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与专注于专业药房市场的公司有关。
专科药房市场的一些主要参与者包括 McKesson Canada、Bayshore HealthCare、SRx Health、Sentrex Health Solutions、Sobeys Inc.、PHARMASAVE、Lovell Drugs、Create Compounding Ltd.、Dynasty Pharmacy、Resident Care Pharmacy、Pace Pharmacy、Northmount Pharmacy and Compounding Lab、Medicine Centre、riverviewguardian.ca、Brunskillpharmacy、Extend Pharmacy、Sherman Specialty Pharmacy、Quiick Medicine、Allcures Pharmacy、Alpine Drug Mart IDA、PharmaChoiceAnchor Compounding Pharmacy、Andreen's Pharmacy、Balanced Health Integrative Pharmacy、Bains Pharmacy、Shoppers Drug Mart Specialty Health Network Inc. 和 MEDS 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE CANADA SPECIALTY PHARMACY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 SERVICE TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 CANADA SPECIALTY PHARMACY MARKET, DISTRIBUTION MODEL
4.4 CANADA SPECIALTY PHARMACY MARKET, KEY STRATEGIC INITIATIVES
4.5 CANADA SPECIALTY PHARMACY MARKET, PATIENT ASSISTANCE PROGRAMS IN CANADA
4.6 CANADA SPECIALTY PHARMACY MARKET, INDUSTRY INSIGHTS
4.7 CANADA SPECIALTY PHARMACY MARKET, REGULATIONS
5 LIST OF SMALL ENTERPRISES
6 EPIDEMEOLOGY
7 COUNTRY WRITE-UP
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASING PREVALENCE OF CHRONIC AND RARE DISEASES
8.1.2 INCREASING GERIATRIC POPULATION
8.1.3 INSURANCE COVERAGE
8.1.4 INCREASING NUMBER OF DISTRIBUTION CHANNELS FOR SPECIALITY DRUGS
8.2 RESTRAINTS
8.2.1 STRINGENT REGULATORY FRAMEWORK
8.2.2 LACK OF SKILLED PHARMACISTS
8.3 OPPORTUNITIES
8.3.1 EMERGING MARKETS OF SPECIALTY PHARMACIES
8.3.2 RISING E-PHARMACIES FACILITIES
8.4 CHALLENGES
8.4.1 LACK OF AWARENESS AMONG CONSUMERS ABOUT SPECIALTY PHARMACIES
8.4.2 INSUFFICIENT FUNDING FOR SPECIALITY PHARMACIES
9 CANADA SPECIALTY PHARMACY MARKET, BY SERVICE TYPE
9.1 OVERVIEW
9.2 CLINICAL SERVICES
9.2.1 COMPOUNDING
9.2.2 AUTO-REFILLS/REFILLS
9.2.3 BLISTER PACKAGING
9.2.4 MEDICAL CONSULTATIONS
9.2.4.1 PATIENT SIDE EFFECTS
9.2.4.2 ADVERSE DRUG REACTIONS
9.2.4.3 NON-COMPLIANCE
9.2.4.4 OTHER PATIENT CONCERNS
9.2.5 CARE MANAGEMENT
9.2.6 PATIENT ADHERENCE PROGRAMS
9.2.7 HEALTH CARE PROVIDER ACCESS
9.2.8 CLINICAL OUTCOME MEASURES
9.2.9 RISK EVALUATION AND MITIGATION STRATEGIES (REMS) PROGRAMS
9.2.9.1 REMS REPORTING
9.2.9.2 PHASE IV TRIALS
9.2.9.3 CLINICAL AND COGNITIVE COUNSELING
9.3 OPERATIONAL SERVICES
9.3.1 SUPPLY CHAIN MANAGEMENT
9.3.1.1 STORAGE & HANDLING
9.3.1.2 DISTRIBUTION
9.3.2 CARE COORDINATION
9.3.3 INSURANCE NAVIGATION
9.3.3.1 UTILIZATION MANAGEMENT
9.3.3.2 PRIOR AUTHORIZATION PROCESSES
9.3.4 PATIENT ASSISTANCE
9.3.5 PLAN OPTIMIZATION
9.4 OTHER SERVICES
10 CANADA SPECIALTY PHARMACY MARKET, BY TYPE
10.1 OVERVIEW
10.2 LARGE PHARMACY BENEFIT MANAGER (PBM)
10.2.1 MANUFACTURER-OWNED SPECIALTY PHARMACIES
10.2.2 OWNED SPECIALTY PHARMACIES
10.3 SMALL INDEPENDENT PHARMACY SERVICE PROVIDERS
11 CANADA SPECIALTY PHARMACY MARKET, BY CONDITION
11.1 OVERVIEW
11.2 CANCER
11.3 RHEUMATOID ARTHRITIS
11.4 MULTIPLE SCLEROSIS
11.5 OSTEOARTHRITIS
11.6 INFERTILITY
11.7 HIV
11.8 PULMONARY HYPERTENSION
11.9 IMMUNE DEFICIENCY
11.1 ANEMIA
11.11 HEMOPHILIA
11.12 PSORIASIS
11.13 CYSTIC FIBROSIS
11.14 ULCERATIVE COLITIS
11.15 CROHN’S DISEASE
11.16 JUVENILE IDIOPATHIC ARTHRITIS
11.17 GROWTH HORMONE DEFICIENCIES
11.18 HEPATITIS C VIRUS
11.19 OTHERS
12 CANADA SPECIALTY PHARMACY MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: CANADA
13 SWOT ANALYSIS
14 COMPANY PROFILES
14.1 BAYSHORE HEALTHCARE
14.1.1 COMPANY SNAPSHOT
14.1.2 PRODUCT PORTFOLIO
14.1.3 RECENT DEVELOPMENTS
14.2 MCKESSON CANADA
14.2.1 COMPANY SNAPSHOT
14.2.2 PRODUCT PORTFOLIO
14.2.3 RECENT DEVELOPMENTS
14.3 SOBEYS INC.
14.3.1 COMPANY SNAPSHOT
14.3.2 PRODUCT PORTFOLIO
14.3.3 RECENT DEVELOPMENTS
14.4 AURORA HEALTH CARE
14.4.1 COMPANY SNAPSHOT
14.4.2 PRODUCT PORTFOLIO
14.4.3 RECENT DEVELOPMENTS
14.5 REXALL PHARMACY GROUP ULC
14.5.1 COMPANY SNAPSHOT
14.5.2 PRODUCT PORTFOLIO
14.5.3 RECENT DEVELOPMENTS
14.6 ANDREEN'S PHARMACY
14.6.1 COMPANY SNAPSHOT
14.6.2 PRODUCT PORTFOLIO
14.6.3 RECENT DEVELOPMENTS
14.7 ALPINE DRUG MART I.D.A.
14.7.1 COMPANY SNAPSHOT
14.7.2 PRODUCT PORTFOLIO
14.7.3 RECENT DEVELOPMENTS
14.8 ALLCURES PHARMACY
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENTS
14.9 ABBY PHARMACY
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENTS
14.1 AARONSON'S COMPOUNDING PHARMACY
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENTS
14.11 BALANCED HEALTH INTEGRATIVE PHARMACY
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 1.11. 3 RECENT DEVELOPMENTS
14.12 BRUNSKILLPHARMACY
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 BUDGET PHARMACY
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENTS
14.14 BIOSCRIPT SOLUTIONS
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENT
14.15 BAINS PHARMACY
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENTS
14.16 360CARE DENMAN PHARMACY
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENTS
14.17 COMPOUNDING PHARMACY NEW WESTMINSTER- LONGEVITY PHARMACY
14.17.1 COMPANY SNAPSHOT
14.17.2 PRODUCT PORTFOLIO
14.17.3 RECENT DEVELOPMENTS
14.18 CITY LIFE PHARMACY & COMPOUNDING CENTRE
14.18.1 COMPANY SNAPSHOT
14.18.2 PRODUCT PORTFOLIO
14.18.3 RECENT DEVELOPMENTS
14.19 CREATE COMPOUNDING LTD.
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENTS
14.2 CONCORD SPECIALTY PHARMACY
14.20.1 COMPANY SNAPSHOT
14.20.2 PRODUCT PORTFOLIO
14.20.3 1.20.3RECENT DEVELOPMENTS
14.21 DYNASTY PHARMACY
14.21.1 COMPANY SNAPSHOT
14.21.2 PRODUCT PORTFOLIO
14.21.3 RECENT DEVELOPMENTS
14.22 EXTEND PHARMACY
14.22.1 COMPANY SNAPSHOT
14.22.2 PRODUCT PORTFOLIO
14.22.3 RECENT DEVELOPMENTS
14.23 LOVELL DRUGS
14.23.1 COMPANY SNAPSHOT
14.23.2 PRODUCT PORTFOLIO
14.23.3 RECENT DEVELOPMENTS
14.24 LONDON DRUGS
14.24.1 COMPANY SNAPSHOT
14.24.2 PRODUCT PORTFOLIO
14.24.3 RECENT DEVELOPMENT
14.25 MCCALLUM PHARMACY
14.25.1 COMPANY SNAPSHOT
14.25.2 PRODUCT PORTFOLIO
14.25.3 RECENT DEVELOPMENTS
14.26 MEDLANDIA.COM
14.26.1 COMPANY SNAPSHOT
14.26.2 PRODUCT PORTFOLIO
14.26.3 RECENT DEVELOPMENTS
14.27 MEDICINE CENTRE
14.27.1 COMPANY SNAPSHOT
14.27.2 PRODUCT PORTFOLIO
14.27.3 RECENT DEVELOPMENTS
14.28 MOUNTAIN HEALTH CO-OP
14.28.1 COMPANY SNAPSHOT
14.28.2 PRODUCT PORTFOLIO
14.28.3 RECENT DEVELOPMENTS
14.29 MEDS PHARMACY
14.29.1 COMPANY SNAPSHOT
14.29.2 PRODUCT PORTFOLIO
14.29.3 RECENT DEVELOPMENTS
14.3 NORTHMOUNT PHARMACY AND COMPOUNDING LAB
14.30.1 COMPANY SNAPSHOT
14.30.2 PRODUCT PORTFOLIO
14.30.3 RECENT DEVELOPMENTS
14.31 NKS HEALTH (A SUBSIDIARY OF GREEN SHIELD)
14.31.1 COMPANY SNAPSHOT
14.31.2 PRODUCT PORTFOLIO
14.31.3 RECENT DEVELOPMENTS
14.32 ON-PHARM UNITED
14.32.1 COMPANY SNAPSHOT
14.32.2 PRODUCT PORTFOLIO
14.32.3 RECENT DEVELOPMENTS
14.33 OMNICARE PHARMACY
14.33.1 COMPANY SNAPSHOT
14.33.2 PRODUCT PORTFOLIO
14.33.3 RECENT DEVELOPMENTS
14.34 OMNICELL INC. (2022)
14.34.1 COMPANY SNAPSHOT
14.34.2 REVENUE ANALYSIS
14.34.3 PRODUCT PORTFOLIO
14.34.4 RECENT DEVELOPMENT
14.35 PHARMACHOICEANCHOR COMPOUNDING PHARMACY
14.35.1 COMPANY SNAPSHOT
14.35.2 PRODUCT PORTFOLIO
14.35.3 RECENT DEVELOPMENTS
14.36 PHARMACHOICE
14.36.1 COMPANY SNAPSHOT
14.36.2 PRODUCT PORTFOLIO
14.36.3 RECENT DEVELOPMENTS
14.37 PRATT'S COMPOUNDING PHARMACY
14.37.1 COMPANY SNAPSHOT
14.37.2 PRODUCT PORTFOLIO
14.37.3 RECENT DEVELOPMENTS
14.38 PHARMASAVE
14.38.1 COMPANY SNAPSHOT
14.38.2 PRODUCT PORTFOLIO
14.38.3 RECENT DEVELOPMENTS
14.39 PACE PHARMACY
14.39.1 COMPANY SNAPSHOT
14.39.2 PRODUCT PORTFOLIO
14.39.3 RECENT DEVELOPMENTS
14.4 QUIICK MEDICINE
14.40.1 COMPANY SNAPSHOT
14.40.2 PRODUCT PORTFOLIO
14.40.3 RECENT DEVELOPMENTS
14.41 RESIDENT CARE PHARMACY
14.41.1 COMPANY SNAPSHOT
14.41.2 PRODUCT PORTFOLIO
14.41.3 RECENT DEVELOPMENTS
14.42 RIVERVIEWGUARDIAN.CA
14.42.1 COMPANY SNAPSHOT
14.42.2 PRODUCT PORTFOLIO
14.42.3 RECENT DEVELOPMENTS
14.43 RX CONNECT
14.43.1 COMPANY SNAPSHOT
14.43.2 PRODUCT PORTFOLIO
14.43.3 RECENT DEVELOPMENTS
14.44 SRX HEALTH
14.44.1 COMPANY SNAPSHOT
14.44.2 PRODUCT PORTFOLIO
14.44.3 RECENT DEVELOPMENTS
14.45 SENTREX HEALTH SOLUTIONS
14.45.1 COMPANY SNAPSHOT
14.45.2 PRODUCT PORTFOLIO
14.45.3 RECENT DEVELOPMENTS
14.46 SHOPPERS DRUG MART SPECIALTY HEALTH NETWORK INC.
14.46.1 COMPANY SNAPSHOT
14.46.2 PRODUCT PORTFOLIO
14.46.3 RECENT DEVELOPMENTS
14.47 SHERMAN SPECIALTY PHARMACY
14.47.1 COMPANY SNAPSHOT
14.47.2 PRODUCT PORTFOLIO
14.47.3 RECENT DEVELOPMENTS
14.48 TORANI AND HADDAD PHARMACY SPEC- PHARMA
14.48.1 COMPANY SNAPSHOT
14.48.2 PRODUCT PORTFOLIO
14.48.3 RECENT DEVELOPMENTS
14.49 TOTAL PHARMACY
14.49.1 COMPANY SNAPSHOT
14.49.2 PRODUCT PORTFOLIO
14.49.3 RECENT DEVELOPMENTS
14.5 VICTORIA COMPOUNDING PHARMACY
14.50.1 COMPANY SNAPSHOT
14.50.2 PRODUCT PORTFOLIO
14.50.3 RECENT DEVELOPMENTS
14.51 WEST END PHARMACY
14.51.1 COMPANY SNAPSHOT
14.51.2 PRODUCT PORTFOLIO
14.51.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
表格列表
TABLE 1 LIST OF SMALL ENTERPRISES
TABLE 2 DATA OF NUMBER OF ELDERLY POPULATION IN CANADA
TABLE 3 CANADA HEALTHCARE (2018-2009)
TABLE 4 CANADA SPECIALTY PHARMACY MARKET, BY SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 5 CANADA CLINICAL SERVICES IN SPECIALTY PHARMACY MARKET, BY SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 6 CANADA MEDICAL CONSULTATIONS IN SPECIALTY PHARMACY MARKET, BY SERVICE TYPE 2021-2030 (USD MILLION)
TABLE 7 CANADA RISK EVALUATION AND MITIGATION STRATEGY (REMS) IN SPECIALTY PHARMACY MARKET, BY SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 8 CANADA OPERATIONAL SERVICES IN CANADA SPECIALTY PHARMACY MARKET, BY SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 9 CANADA SUPPLY CHAIN MANAGEMENT IN SPECIALTY PHARMACY MARKET, BY SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 10 CANADA INSURANCE NAVIGATION IN SPECIALTY PHARMACY MARKET, BY SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 11 CANADA SPECIALTY PHARMACY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 12 CANADA LARGE PHARMACY BENEFIT MANAGER (PBM) IN SPECIALTY PHARMACY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 13 CANADA SPECIALTY PHARMACY MARKET, BY CONDITION, 2021-2030 (USD MILLION)
TABLE 14 PREVALENCE (%) OF DIAGNOSED OSTEOARTHRITIS BY SEX AND AGE GROUP, CANADA
TABLE 15 HEMOPHILIA PREVALENCE BY IN BOTH GENDER
TABLE 16 PREVALENCE (%) OF DIAGNOSED JUVENILE IDIOPATHIC ARTHRITIS BY SEX AND AGE GROUP, CANADA
图片列表
FIGURE 1 CANADA SPECIALTY PHARMACY MARKET: SEGMENTATION
FIGURE 2 CANADA SPECIALTY PHARMACY MARKET: DATA TRIANGULATION
FIGURE 3 CANADA SPECIALTY PHARMACY MARKET: DROC ANALYSIS
FIGURE 4 CANADA SPECIALTY PHARMACY MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 CANADA SPECIALTY PHARMACY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 CANADA SPECIALTY PHARMACY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 CANADA SPECIALTY PHARMACY MARKET: DBMR MARKET POSITION GRID
FIGURE 8 CANADA SPECIALTY PHARMACY MARKET: DBMR VENDOR SHARE ANALYSIS
FIGURE 9 CANADA SPECIALTY PHARMACY MARKET: SEGMENTATION
FIGURE 10 AN INCREASE IN THE PREVALENCE OF CHRONIC AND RARE DISEASES IS EXPECTED TO BOOST THE CANADA SPECIALTY PHARMACY MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 11 CLINICAL SERVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE CANADA SPECIALTY PHARMACY MARKET IN 2023 & 2030
FIGURE 12 DISTRIBUTION AND DISPENSE OF SPECIALTY DRUGS UNDER THE PHARMACY BENEFIT
FIGURE 13 DISTRIBUTION AND DISPENSE OF SPECIALTY DRUGS UNDER THE MEDICAL BENEFIT
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE CANADA SPECIALTY PHARMACY MARKET
FIGURE 15 CANADA SPECIALTY PHARMACY MARKET: BY SERVICE TYPE, 2022
FIGURE 16 CANADA SPECIALTY PHARMACY MARKET: BY SERVICE TYPE, 2023-2030 (USD MILLION)
FIGURE 17 CANADA SPECIALTY PHARMACY MARKET: BY SERVICE TYPE, CAGR (2023-2030)
FIGURE 18 CANADA SPECIALTY PHARMACY MARKET: BY SERVICE TYPE, LIFELINE CURVE
FIGURE 19 CANADA SPECIALTY PHARMACY MARKET: BY TYPE, 2022
FIGURE 20 CANADA SPECIALTY PHARMACY MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 21 CANADA SPECIALTY PHARMACY MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 22 CANADA SPECIALTY PHARMACY MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 CANADA SPECIALTY PHARMACY MARKET: BY CONDITION, 2022
FIGURE 24 CANADA SPECIALTY PHARMACY MARKET: BY CONDITION, 2023-2030 (USD MILLION)
FIGURE 25 CANADA SPECIALTY PHARMACY MARKET: BY CONDITION, CAGR (2023-2030)
FIGURE 26 CANADA SPECIALTY PHARMACY MARKET: BY CONDITION, LIFELINE CURVE
FIGURE 27 CANADA SPECIALTY PHARMACY MARKET: COMPANY SHARE 2022 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
